Cyclosporine shows promise in treatment of moderate-to-severe alopecia areata
Treatment with cyclosporine results in improvements, albeit statistically nonsignificant, in the Severity of Alopecia Tool score and eyelash and eyebrow assessment scales among patients with moderate-to-severe alopecia areata (AA), a recent study has shown.
Thirty-two patients were included in the analysis, of whom 16 received cyclosporine and 16 placebo. A greater proportion of participants in the cyclosporine group achieved at least a 50-percent reduction in the Severity of Alopecia Tool score (31.3 percent vs 6.3 percent; p=0.07) and a 1-grade improvement in eyelash (18.8 percent vs 0 percent; p=0.07) and eyebrow (31.3 percent vs 0 percent; p=0.02) scale score compared with those in the placebo group.
“Small sample size and single-institution trial may limit interpretation and generalizability of these results,” the investigators said.
In another study, treatment with oral cyclosporin for moderate-to-severe AA for 3 months resulted in trends for improvement in quality of life across multiple dimensions in both disease-specific and generic measures. [J Dermatolog Treat 2019;doi:10.1080/09546634.2019.1654068]
This double-blind, randomized, placebo-controlled trial was performed to assess the efficacy of cyclosporine compared with placebo in patients aged 18–65 years with moderate-to-severe AA. Participants were randomized 1:1 to receive 3 months of cyclosporine (4 mg/kg/d) or matching placebo.
Blinded assessments included the following: physical examination, blood biochemistry, photography, quality of life measurements, and efficacy evaluation using the Severity of Alopecia Tool score and eyelash and eyebrow assessment scales.
AA is a common autoimmune disease that often results in unpredictable hair loss with substantial psychological burden.